International Journal of Versatile Research and Analysis · Aug 2026
DAPAGLIFLOZIN IN ELDERLY PATIENTS WITH TYPE 2 DIABETES AND HYPERTENSION: A FOCUSED REVIEW ON BLOOD PRESSURE CONTROL, RENAL SAFETY, AND PRACTICAL DOSING IN GERIATRIC POLYPHARMACY
By S KR, Andhuvan G, Sriram S
Older adults with type 2 diabetes mellitus (T2DM) and hypertension are at a substantially increased risk of cardiovascular and renal complications, with disease management often complicated by multimorbidity and polypharmacy. Dapagliflozin, a sodium–glucose cotransporter-2 (SGLT2) inhibitor, has demonstrated clinical benefits that extend beyond glycaemic control, including improvements in blood pressure, renal outcomes, and cardiovascular health. This review evaluates the current evidence regarding the efficacy, safety, and practical application of dapagliflozin in elderly patients with T2DM and hypertension. Findings from randomized controlled trials, meta-analyses, and real-world studies indicate that dapagliflozin provides effective glycaemic control, slows the progression of chronic kidney disease, and reduces the risk of heart failure and cardiovascular events across older age groups. The review also discusses age-related physiological changes, potential drug interactions, and the challenges associated with polypharmacy, emphasizing the importance of individualized treatment, careful assessment of renal function, and regular monitoring of hydration status. In addition, practical recommendations for treatment initiation, dose optimization, follow-up, and management during acute illness are presented. Overall, dapagliflozin demonstrates a favourable benefit–risk profile and represents a valuable therapeutic option for elderly patients when prescribed with individualized monitoring and appropriate clinical supervision